The global pharmaceutical gelatin market size is expected to advance at a CAGR of 5.6% during 2024–2030, to reach USD 1,703.4 million by 2030. This can be ascribed to the unique functional properties of gelatin used in various medical, biomedical, biotechnology, and pharmaceutical applications; and its rising demands in the nutrition, cosmetics, food, and healthcare industries for producing novel products.
Moreover, gelatin is a natural substance that can be used for transporting medications, such as resveratrol, cycloheximide, and doxorubicin for cancer therapy. Gelatin nanoparticles have been suggested as an option for parenteral formulations because of their low cost, biocompatibility, biodegradability, reduced antigenicity, and applications in a range of formulations. Thus, the market will rise as a result of the usage of pharmaceutical gelatin in parenteral medication delivery systems.
The rising need for advanced drugs boosts the demand for pharmaceutical gelatin, as it is a raw material for producing medicine. As the incidences of various diseases increase and in order to meet the surging needs of patients, manufacturers are being urged to produce novel drugs that can be used for the treatment of such conditions. Also, numerous regional and significant industry players often focus on creating new goods in order to stay competitive in the industry. Thus, the launches of new products generate profitable prospects for pharmaceutical gelatin.
For instance, in November 2022, scientists from the Terasaki Institute for Biomedical Innovation (TIBI) created a new injectable hydrogel with the help of a gelatin compound for the treatment of aneurysms. This injectable hydrogel promotes greater cohesion, surges affinity for blood components for quicker coagulation, and activates initiation of the coagulation process.
Similarly, in December 2022, Darling Ingredients Inc. announced that its health brand Rousselot received the U.S. patent for SiMoGel. This is a gelatin technology that enables the production of nutraceutical gummies and eliminates the need for starch-based gummy production.
Gelatin is divided into type A and type B. Of these, the type A category is projected to witness the faster growth during the forecast period. This can be because type A gelatin that is obtained from pig skin exhibits high-storage stability and its popularity is increasing among end users.
The Asia-Pacific market is expected to grow at a CAGR of 6.1% during the forecast period. This growth can be attributed to the easy availability of raw materials; the presence of capsule manufacturers; the surging demand for novel drugs for the treatment of various chronic diseases such as diabetes, cancer, cardiovascular, and osteoarthritis; and the increasing need for gelatin for many pharmaceutical dosage forms like tablets, capsules, emulsions, and injections, in the region.
Moreover, the rising government initiatives to make a better healthcare system and improve R&D activities will lead the market growth. In addition, industry players are putting emphasis on strengthening their distribution networks in the region and expanding their regional consumption of pharmaceutical gelatin for gene delivery, protein delivery, ocular drug delivery, pulmonary medication administration, and others, to take advantage of ample growth opportunities.
Some of the major pharmaceutical gelatin market players are Darling Ingredients Inc., Tessenderlo Group, Gelita AG, Nitta Gelatin NA Inc., Gelnex, Aspire Pharmaceuticals, and SAS Gelatines Weishardt.